ArticleAdvances in therapy2023

Cost-Effectiveness Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) Versus Standard of Care for the Prevention of Recurrent Clostridioides difficile Infection in the USA.

Thomas Lodise et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.